Stocks Health care FDMT
NASDAQ · Health care4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. brought in $92M of revenue over the twelve months to June 30, 2026, up 278,712.1% from a year earlier. It posted a net loss of $179.2M. In fiscal 2025 capital spending exceeded operating cash flow by $109.6M. At June 30, 2026 it held $70.4M in cash against $19.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about 4D Molecular Therapeutics, Inc.
- Net worth
- 4D Molecular Therapeutics, Inc. has a market value (market cap) of $689.4M at the latest share price, and shareholders' equity of $407.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $85.2M (+230,194.6% year on year), with a net loss of $140.1M. Over the 12 months to June 30, 2026: revenue $92M, net loss $179.2M.
- Cash flow
- In fiscal 2025 operations used $109.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- 4D Molecular Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What 4D Molecular Therapeutics, Inc. does
4D Molecular Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FDMT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $85.2M | -$140.1M | -$2.42 | -$109.6M |
| 2024 | $37K | -$160.9M | -$2.98 | -$138.4M |
| 2023 | $20.7M | -$100.8M | -$2.58 | -$78.6M |
| 2022 | $3.1M | -$107.5M | -$3.32 | -$98.2M |
| 2021 | $18M | -$71.3M | -$2.57 | -$78.2M |
| 2020 | $13.6M | -$56.7M | -$8.82 | -$51.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FDMT ranks in Health care
Latest SEC filings
What 4D Molecular Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 25,107% to $3.8M versus the same quarter last year; diluted EPS -$1.04 versus -$0.98.
- August 13, 2026
- July 20, 2026Other event 8-K
- June 29, 2026
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
- May 7, 2026
Insider trades
What the people running 4D Molecular Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 16, 2026 | Bizily ScottChief Legal Officer | Exercised options | 1,635 | $6.8K |
| October 16, 2026 | Bizily ScottChief Legal Officer | Soldpre-planned (10b5-1) | 1,635 | $21K |
| October 5, 2026 | Kirn DavidSee Remarks, Director | Soldpre-planned (10b5-1) | 58,061 | $750.2K |
| October 5, 2026 | Kirn DavidSee Remarks, Director | Soldpre-planned (10b5-1) | 272 | $3.7K |
| September 16, 2026 | Bizily ScottChief Legal Officer | Exercised options | 1,635 | $6.8K |
| September 16, 2026 | Bizily ScottChief Legal Officer | Soldpre-planned (10b5-1) | 1,635 | $22.3K |
| September 14, 2026 | Kirn DavidSee Remarks, Director | Soldpre-planned (10b5-1) | 58,333 | $811K |
| September 1, 2026 | Bizily ScottChief Legal Officer | Exercised options | 584 | $3.8K |
Who owns FDMT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 10.3% | April 7, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | May 15, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | May 15, 2026 |
| Novo Holdings A/S13G, passive | 6.4% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 158 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 5,746,289 | new |
| RA Capital Management, L.P. | 5,049,779 | 0 |
| BlackRock, Inc. | 4,546,059 | +400,756 |
| Goldman Sachs Group Inc | 4,258,668 | +53,230 |
| Novo Holdings A/S | 3,249,178 | -401,559 |
| State Street Corp | 2,911,109 | +203,234 |
| Bvf Inc | 2,879,289 | 0 |
| Adage Capital Partners GP, L.L.C. | 2,249,203 | +644,047 |
| Trails Edge Capital Partners, LP | 2,227,917 | +925,000 |
| Vanguard Capital Management LLC | 2,099,055 | -96,523 |
| Armistice Capital, LLC | 2,000,000 | 0 |
| Geode Capital Management, LLC | 1,128,466 | +63,121 |
| Bank of America Corp | 1,120,674 | +146,501 |
| Evergreen Quality Fund GP, Ltd. | 951,474 | 0 |
| Parkman Healthcare Partners LLC | 948,184 | +425,607 |
| Dimensional Fund Advisors LP | 730,857 | +208,034 |
| Deutsche Bank AG\ | 710,942 | +2,898 |
| Citadel Advisors LLC | 687,597 | +423,501 |
| Renaissance Technologies LLC | 614,573 | +36,308 |
| Vanguard Portfolio Management LLC | 579,903 | +24,074 |
Insiders
4 insiders reported holding 806,509 shares in total, about $10.1M at the last price.
| Holder | Shares |
|---|---|
| Kirn DavidSee Remarks, Director | 709,153 |
| Gupta AshooVP, Finance and Controller | 47,055 |
| Theuer CharlesDirector | 41,684 |
| Bizily ScottChief Legal Officer | 8,617 |
Questions about FDMT
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as FDMT. Its shares trade on NASDAQ under the ticker FDMT.
What is 4D Molecular Therapeutics, Inc.'s net worth?
4D Molecular Therapeutics, Inc. has a market value (market cap) of $689.4M at the latest share price, and shareholders' equity of $407.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is 4D Molecular Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $179.2M on revenue of $92M.
How much revenue does 4D Molecular Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 4D Molecular Therapeutics, Inc. reported revenue of $92M. That is 278,712.1% more than a year earlier.
When did 4D Molecular Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 20, 2026.
When is 4D Molecular Therapeutics, Inc.'s next earnings report?
4D Molecular Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare FDMT with
Follow FDMT
Get an email when 4D Molecular Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values 4D Molecular Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.